AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
AEON Biopharma Appoints John Bencich as Chief Financial Officer